EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo

Hengkang Yan iD, Sakshi Arora iD, Linda Hii, Carmen Llerena, Mary E Vail iD, Amr Allam, James R W Conway, Joel R Steele, Han-Chung Lee iD, Ralf B Schittenhelm iD, Andrew M Scott, Peter W Janes iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262110684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hengkang Yan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia. Hauptthemen laut MEDLINE: ADAM10 Protein, Glioblastoma, Amyloid Precursor Protein Secretases, Signal Transduction. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tour de cure, National Health and Medical Research Council, Tour de Cure Pioneering grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ADAM10 is a transmembrane metalloprotease that regulates diverse signalling functions via the shedding of membrane protein ectodomains, and is implicated in tumour development, including glioblastoma multiforme (GBM) and gastrointestinal (GI) cancers, where high ADAM10 expression is associated with poor prognosis. We assessed the role of ADAM10 by gene knockout (KO) in U251 GBM cells, and its effects on protein shedding and protein expression on cell proliferation and on the growth of tumour xenografts in mice. The growth of tumours was severely delayed, relative to modest effects on proliferation in vitro, suggesting roles particularly in the context of the tumour microenvironment (TME). Proteomics analysis of KO cell-conditioned medium showed decreased levels of known ADAM10 targets such as Notch and Eph receptors and ligands, as well as other proteins involved in cell–cell adhesion, migration, signalling, metabolism, differentiation, and development, including angiogenesis. KO cell and tumour lysate analysis also showed modulation of proteins associated with metabolic and catalytic activity, cell–matrix organisation and differentiation. Similar effects were also observed in the SW620 colon cancer model, indicating broader significance. Furthermore, expression of the associated protein sets also correlated with ADAM10 expression in human GBM and colon cancer specimens (TCGA datasets), indicating clinical relevance. Collagens and proteins associated with matrix deposition and fibril organisation were notably reduced in ADAM10 KO GBM tumours, and histology confirmed decreased collagen fibrils and blood vessels. Unexpectedly, increased chondrocyte differentiation was evident in ADAM10 KO U251 tumours, suggesting a role for ADAM10 in maintaining an undifferentiated phenotype in vivo. Together, our data indicate the importance of ADAM10 in diverse signalling mechanisms in tumours and the TME that promote tumour development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAM10 ProteinGlioblastomaAmyloid Precursor Protein SecretasesSignal TransductionColonic NeoplasmsMembrane ProteinsBrain NeoplasmsHumansAnimalsMiceCell Line, TumorTumor MicroenvironmentCell ProliferationGene Knockout TechniquesGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

ADAM metalloproteaseglioblastomaproteomicstumour microenvironment

Substanzen

ADAM10 ProteinAmyloid Precursor Protein SecretasesADAM10 protein, humanMembrane Proteins

Autor:innen und Institutionen

  • Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
  • School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3084, Australia.
  • Biomedical Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
  • Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.
  • Proteomics & Metabolomics Platform, Monash University, Clayton, VIC 3800, Australia.

ORCID-Profile: Hengkang Yan, Sakshi Arora, Mary E Vail, Han-Chung Lee, Ralf B Schittenhelm, Peter W Janes

Förderung

  • Tour de cure
  • National Health and Medical Research Council
  • Tour de Cure Pioneering grant
  • Victorian Government Operational Infrastructure Support Program

Zitieren

APA

Yan, H., Arora, S., Hii, L., Llerena, C., Vail, M. E., Allam, A., Conway, J. R. W., Steele, J. R., Lee, H. C., Schittenhelm, R. B., Scott, A. M., & Janes, P. W. (2025). ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110684

Vancouver

Yan H, Arora S, Hii L, Llerena C, Vail ME, Allam A, et al. ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110684

BibTeX
@article{Yan2025,
  author = {Yan, Hengkang and Arora, Sakshi and Hii, Linda and Llerena, Carmen and Vail, Mary E and Allam, Amr and Conway, James R W and Steele, Joel R and Lee, Han-Chung and Schittenhelm, Ralf B and Scott, Andrew M and Janes, Peter W},
  title = {ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262110684}
}
Kostenlos starten →